OSE Immunotherapeutics SA/€OSE
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About OSE Immunotherapeutics SA
OSE Immunotherapeutics SA is a biotechnology company focused on the research and development of immunotherapies in the fields of immune-oncology, autoimmune diseases, and transplantation. The company aims to innovate through its pipeline, which includes products such as Tedopi, a therapeutic vaccine for non-small cell lung cancer, and CoVepiT, a COVID-19 vaccine. Founded in 2012 and headquartered in Nantes, France, OSE Immunotherapeutics combines strong scientific expertise with a strategic emphasis on building a diversified portfolio of advanced clinical trials. The company's competitive strength lies in its proprietary technologies and strategic partnerships, enhancing its capabilities to address significant unmet medical needs globally.
Ticker
€OSE
Sector
Primary listing
PAR
Industry
Biotechnology
Headquarters
Employees
64
Website
OSE Metrics
BasicAdvanced
€154M
4.56
€1.48
0.58
-
Price and volume
Market cap
€154M
Beta
0.58
52-week high
€11.58
52-week low
€4.42
Average daily volume
102K
Financial strength
Current ratio
3.458
Quick ratio
1.033
Long term debt to equity
60.081
Total debt to equity
72.295
Interest coverage (TTM)
13.79%
Profitability
EBITDA (TTM)
49.255
Gross margin (TTM)
100.00%
Net profit margin (TTM)
44.88%
Operating margin (TTM)
52.42%
Effective tax rate (TTM)
5.99%
Revenue per employee (TTM)
€1,300,000
Management effectiveness
Return on assets (TTM)
26.54%
Return on equity (TTM)
86.29%
Valuation
Price to earnings (TTM)
4.559
Price to revenue (TTM)
1.764
Price to book
2.31
Price to tangible book (TTM)
2.32
Price to free cash flow (TTM)
3.043
Free cash flow yield (TTM)
32.86%
Free cash flow per share (TTM)
2.218
Growth
Revenue change (TTM)
3,646.52%
Earnings per share change (TTM)
-223.73%
3-year revenue growth (CAGR)
46.93%
3-year earnings per share growth (CAGR)
16.22%
10-year earnings per share growth (CAGR)
14.93%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for OSE Immunotherapeutics SA stock?
OSE Immunotherapeutics SA (OSE) has a market cap of €154M as of July 30, 2025.
What is the P/E ratio for OSE Immunotherapeutics SA stock?
The price to earnings (P/E) ratio for OSE Immunotherapeutics SA (OSE) stock is 4.56 as of July 30, 2025.
Does OSE Immunotherapeutics SA stock pay dividends?
No, OSE Immunotherapeutics SA (OSE) stock does not pay dividends to its shareholders as of July 30, 2025.
When is the next OSE Immunotherapeutics SA dividend payment date?
OSE Immunotherapeutics SA (OSE) stock does not pay dividends to its shareholders.
What is the beta indicator for OSE Immunotherapeutics SA?
OSE Immunotherapeutics SA (OSE) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.